Cardio oncology Double Jeopardy

Transcription

1

2 Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015

3 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection Describe first 2 years of ENCORE Implications & future directions

4 Question 1 A 45 year old Alberta woman with early stage breast cancer should be most concerned about: A. Death from breast cancer B. Death from ovarian cancer C. Death from cardiovascular disease D. Death from old age

5 Question 1 A 45 year old Alberta woman with early stage breast cancer should be most concerned about: A. Death from breast cancer B. Death from ovarian cancer C. Death from cardiovascular disease D. Death from old age

6

7

8 Competing causes of death

9 What is going on? Shortand long term treatmenteffects effects Poor understanding of competing risks, particularly in relation to cardiovascular morbidity and mortality Increasingly important given growing numbers of survivors

10 Traditional paradigm in cancer treatment

11 Traditional paradigm in cancer treatment Surgery to remove malignancy SLASH

12 Consequences of surgery Pain Lymphedema Altered vasculature Disability, disfigurement

13 Traditional paradigm in cancer treatment Surgery to remove malignancy Radiation therapy BURN

14 for each Gy of radiation, there is a 7.4% increase in the occurrence of a subsequent major coronary event. Cardiac deaths 27% higher in breast cancer patients treated with RT vs none.

15 Traditional paradigm in cancer treatment Surgery to remove malignancy Radiation therapy Chemotherapyh POISON

16 Consequences of chemotherapy Multiple short and long term toxicities Negative cardiovascular sequelae

17 Anthracyclines Risk factors associated with cardiovascular sequelae Cumulative dose? Age extremes Dose scheduling Mediastinal radiotherapy Previous cardiac events Hypertension females

18

19 Yancik JAMA 2001 N = 1800

20 Figure 1: Multiple-hit hit hypothesis. (Jones, L.W. JACC, 50(15) ). 1441)

21 New paradigm in cancer treatment Surgery to remove malignancy Radiation Therapy Chemotherapyh Targeted Therapy

22 Hallmarks of Cancer: The Next Generation Hanahan & Weinberg, Cell 144, March 4, 2011 Elsevier Inc.

23 Standard treatment for early stage breast cancer Surgery to remove malignancy Chemotherapy Radiation i Therapy Targeted Therapy

24 Trastuzumab in breast cancer Approximately 20 25% 25% of breast cancer patients overexpress human epidermal growth factor for receptor 2 (HER2), a high risk marker for future metastatic disease and a poor prognosis. trastuzumab reduces the 3 year breast cancer recurrence and risk of death rate by half. standard of care since 2006

25 Trastuzumab major side effect Few adverse effects BUT cardiac toxicity, has emerged as a significant complication of trastuzumab treatment. Clinical heart failure (HF) was found in up to 4% of treated patients and asymptomatic declinesin ventricular function have been reported in up to 20% of patients in randomized trials. BC and MB clinical experiences: up to 25% experienced a cardiac event, requiring temporary or permanent discontinuation of trastuzumab

26

27 Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Feldman AM, Koch WJ, Force TL. Clin Pharmacol Ther Jun;81(6): Epub 2007 Mar 28.

28 Q3monthly cardiac assessment while on one year of trastuzumab CCO 2014

29 What is left ventricular ejection fraction (LVEF)?

30 What is Ejection Fraction (EF)? The FRACTION of blood ejected with each heartbeat LVEDV = LVESV = LV end diastolic LV end systolic volume volume LVEDV LVESV / LVEDV The left ventricle as FULL as it can get before contracting The left ventricle as EMPTY as it can get after contracting

31 EF can be deceiving LVEDV LVESV Stroke Volume (LVEDV EF LVESV) 120 ml 50 ml 70mL 60% 135mL 55mL 80mL 60% 150mL 60mL 90mL 60% Cardiac remodeling

32

33 Patient case trastuzumab Baseline 32 year old female Ex smoker Asymptomatic JVP flat, no edema Fatigue (chemo) Elliptical twice weekly

34 3 month echo

35 Issues in detecting cardiotoxicity Clinical symptoms Fatigue Exercise intolerance Pedal edema

36 Why is early detection important? Percentage of Responders According to the Time Elapsed From AC Administration and Start of HF Therapy AC = anthracyclines; HF = heart failure. (Cardinale JACC 2010)

37 Issues in detecting cardiotoxicity Clinical symptoms Fatigue Exercise intolerance Pedal edema Diagnostic imaging i

38 Definitions of trastuzumab related cardiotoxicity trastuzumab mediatedcardiac toxicity as: 1) a cardiomyopathy with a decrease in left ventricular ejection fraction (LVEF), (2) symptoms or signs of heart failure, (3) an absolute decline in LVEF by 5% and < 55% with symptoms of HF or (4) an asymptomatic ti absolute decline in LVEF by 10% and LVEF < 50%. Seidman A,, et al. Cardiac dysfunction in the trastzumab clinical trials experience. J Clin Oncol 2002;20: Mackey JR et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15(1):24-35.

39 Issues in detecting cardiotoxicity MUGA (multi gated acquisition scan) provides LVEF, reproducible Widely available, commonly used in oncology

40 MUGA Radionuclide scan - RBCs are tagged, flow measured by camera

41 Issues in detecting cardiotoxicity MUGA (multi gated acquisition scan) provides EF, reproducible Widely available, commonly used in oncology Echocardiography Provides LVEF AND measures volumes of each heart chamber Technique, expertise dependent d

42 Issues in detecting cardiotoxicity MUGA (multi gated acquisition scan) provides EF, reproducible Widely available, commonly used in oncology Echocardiography Provides EF AND measures volumes of each heart chamber Technique dependent d

43 Issues in detecting cardiotoxicity MUGA (multi gated acquisition scan) provides EF, reproducible Widely available, commonly used in oncology Echocardiography Provides EF AND measures volumes of each heart chamber Technique dependent d Cardiac MRI EF, volumes, multiple other images Not widely available

44 Issues in detecting cardiotoxicity BASELINE LVEDV 120ml, LV mass 91 g, LVEF 55%

45 Issues in detecting cardiotoxicity BASELINE LVEDV 120ml, LV mass 91 g, LVEF 55% FOLLOW UP LVEDV 187ml, LV mass 91 g, LVEF 53%

46

47

48 What can we do?

49 Vision to prevent and treat cardio toxic effects of cancer therapy To develop a rapid access clinic for cancer patients to p p p obtain cardio oncology team assessment

50 Breast Heme CRC Other

51 Adjuvant breast n = baseline 34 (29 trastuzumab, 5 other) during post tx

52 n = 20 completed adjuvant therapy (TCH) average age 55 (32 67) 7 on CVD meds (ACEI, BB, CCB, statin, diuretic) i 5 current, 4 ex smokers (~20PY) 2 + family history CVD BMI Mean 28 11overweight/obese overweight/obese, 9 normal

53 Reason for referral ARRHYTHMIA N = 2 LVEF < 50%, DROP OF > 10% N = 4 LVEF > 50%, DROP OF > 10% N = 14

54 Interventions 100% recommended to continue therapy Additional or other diagnostic imaging 9 (45%) Eh Echo (5), MRI (4) Initiate/change pharmacotherapy 9 (45%) ACEI (4) BB (3) both (1) stop offending med (1)

55 End of treatment cumulative dose N = 20 consult cumulative 100% of planned dose epirubicin docetaxel carboplatin trastuzumab

56 LV function N = Pre consult Post 46 MJGA ECHO MRI

57 Mrs K.

58 retrospective review, n = 48, 85% anthra

59 Anthracycline/trastuzumab? 100% received sequential Fallah-Rad et al JACC anthracycline / trastuzumab Vol 57, No 22, 2011 regimen

60 Why is this important?

61 Best supportive care

62

63 Vision to prevent and treat cardio toxic effects of cancer therapy To develop a rapid access clinic for cancer patients to obtain cardio oncology team assessment To develop a research program involving multidisciplinary and multimodality approaches

64 MANTICORE Overview assessment* MRI biomarkers assessment* MRI biomarkers assessment* MRI biomarkers assessment* MRI biomarkers Randomization medication titration Bisoprolol** 2.5mg 5 10 Perindopril** il** placebo 2mg 4 8 telephone follow up telephone follow up telephone follow up 0 7d 14d 21d mos trastuzumab *assessment = history, physical, labs ** or placebo

65 What can YOU do?

66 A 40 year old breast cancer patient has the cardiopulmonary function of a: A. 40 year old sedentary female B. 50 year old sedentary female C. 60 year old sedentary female D. 70 year old sedentary female

67 A 40 year old breast cancer patient has the cardiopulmonary function of a: A. 40 year old sedentary female B. 50 year old sedentary female C. 60 year old sedentary female D. 70 year old sedentary female

68

69 Courtesy M Haykowsky PHD

70 Modifiable risk factors cardiovascular disease The major modifiable risk factors for cardiovascular disease are well established, and include tobacco use, high blood pressure, high cholesterol, alcohol use, obesity and physical inactivity. Public Health Agency of Canada

71

72 Vital role of comprehensive clinical assessment Health promotion Maintain function, prevention Awareness of short and long term potential effects of cancer treatment Documentation of changes over time Detection of developing problems

73 Cardio oncology oncology Increasingly important Traditional therapies New therapies, targeting vital pathways Heart health promotion major role during therapy full dose of treatment, potentially reduce toxicity long term survivorship, health lthhbit habits, empowerment, family health

74 Team Cross Cancer Institute

75 Thank you!